Drug Trial Radar · NCT06918743
To Evaluate the Efficacy and Safety of RSS0393 Ointment in Patients With Plaque Psoriasis Phase II Study
Last checked: Nov 19, 2026Latest source record: Apr 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
147
Planned (sponsor's estimate)
Start
Apr 2025
Primary completion
Mar 2026
Study completion Mar 2026
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of RSS0393 ointment in patients with plaque psoriasis Phase II study
Conditions
- Psoriatic Subjects
Interventions
RSS0393 ointmentDrug
RSS0393 ointment 0.01%
RSS0393 ointmentDrug
RSS0393 ointment 0.03%
RSS0393 ointment placeboDrug
RSS0393 ointment placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with a clinician's overall assessment (PGA) response (defined as a PGA score of 0 (clear) or 1 (nearly clear) with ≥2 points improvement from baseline)Time frame: 8weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.